ViroLogik GmbH Information

ViroLogik is a biopharmaceutical company which is focusing on innovative drugs for treatment of viral diseases. The focus is on Hepatitis C (HCV). Second indication is HIV- (Human Immunodeficiency Virus, AIDS) infections. ViroLogik is following a novel strategy to prevent formation of drug resistance. ViroLogik has clinical proof of concept with a proteasome inhibitor in Hepatitis C patients refractory to standard therapy. Formal preclinical development of ViroLogik's own development candidate VL-01 is progressing. ViroLogik is following a novel strategy to prevent formation of drug resistance. The approach aims at inhibition of the highly conserved host cell proteasome which is essential for viral replication. This is in contrast to many current drugs which target fast mutating viral proteins and, hence, are prone to induction of drug resistance.